drugset / Trial / NCT05544513

Oral Iron Supplementation for Patients With Chronic Kidney Disease

NCT05544513

Phase 2 Active not recruiting 6 enrolled Fluminense Federal University
RandomizedParallel-groupSingle-blindTreatment

Summary

The hypothesis of this research is that oral iron prescribed in a single dose in alternate day could mitigate the side effects with regard to intestinal microbiota, inflammation, oxidative stress and improve the hematological profile when compared to daily oral iron prescription

Timeline

Start
2022-08-01
Primary completion
2026-12-29
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferrous Sulfate Diagnostic / imaging agent 120 mg Oral
Subject Ferrous Sulfate Diagnostic / imaging agent 240 mg Oral